Abdera Therapeutics

Canada - Vancouver, British Columbia

• 24/04/2023
• Series B
• $142,000,000

Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid development of a broad range of safe and efficacious therapies serving cancer patients with limited treatment options.

Abdera Therapeutics is growing rapidly and seeking key new team members who thrive at the cutting-edge of innovation. Come join us and be a part of the ground-breaking team set to unlock the power of targeted radiotherapy!

Related People

Lori Lyons-WilliamsFounder

United States - San Francisco Bay Area

President and Chief Executive Officer with responsibilities and experience spanning strategy, operations, corporate governance, private and public financings, partnerships, mergers and acquisitions.

Active on Boards of Directors: Director, a stealth company; Independent Director at RAPT Therapeutics (NASDAQ: RAPT, Compensation Committee and Nominating and Corporate Governance Committee); Pipeline Therapeutics (private); former independent director at Five Prime Therapeutics, (NASDAQ: FPRX, Audit and Compensation Committee experience) until its 2021 acquisition by Amgen.

Successful exits:
Chief Commercial Officer at Dermira (NASDAQ: DERM), acquired by Eli Lilly for $1.1B in 2020
Independent Director at Five Prime Therapeutics (NASDAQ: FPRX), acquired by Amgen for $1.9B in 2021

LinkedIn https://www.linkedin.com/in/lorilyonsmba/